Sorafenib CAS 284461-73-0 Purity ≥99.0% (HPLC) API Factory High Quality
Commercial Supply Sorafenib Tosylate and Related Intermediates:
Sorafenib Tosylate CAS: 475207-59-1
Sorafenib CAS: 284461-73-0
4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS: 220000-87-3
4-(4-Aminophenoxy)-N-Methylpicolinamide CAS: 284462-37-9
4-Chloro-3-(Trifluoromethyl)phenyl Isocyanate CAS: 327-78-6
| Name | Sorafenib |
| Synonyms | Sorafenib Free Base |
| CAS Number | 284461-73-0 |
| CAT Number | RF-API04 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C21H16ClF3N4O3 |
| Molecular Weight | 464.82 |
| Density | 1.454±0.06 g/cm3 |
| Solubility | Soluble in DMSO |
| Shipping Conditions | Ambient Temperature |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Off-White Powder |
| Purity / Analysis Method | ≥99.0% (HPLC) |
| Identification | H-NMR, MS |
| Loss on Drying | ≤1.0% |
| Residue on Ignition | ≤0.10% |
| Single Impurity | ≤0.20% (HPLC) |
| Total Impurities | ≤1.0% (HPLC) |
| Heavy Metals | ≤20ppm |
| Clarity of Solution | Conform to Standard |
| Test Standard | Enterprise Standard |
| Usage | RCC & HCC |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Sorafenib Tosylate (CAS: 475207-59-1) is a new type of multi-target antitumor drug, was developed by the German Bayer Pharmaceuticals, and displayed expansive antitumor activity in preclinical animal tests. Sorafenib is available in 200-mg tablets for oral administrationand is used in the treatment of RCC and HCC. Sorafenib Tosylate (CAS: 475207-59-1) can simultaneously affect tumor cells and tumor blood vessels. It has a double antitumor effect: it can block the cell signal transduction pathways mediated by RAF/MEK/ERK to directly inhibit tumor cell growth, while also inhibiting VEGF and platelet derived growth factors (PDGF) receptors to prevent the formation of new tumor blood vessels, thus indirectly inhibiting tumor cell growth. Sorafenib is an inhibitor of Raf-1 and B-RAF as well as several tyrosine kinases.
